Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

NCT ID: NCT06287229

Last Updated: 2025-08-13

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-07-11
• Study Completion Date: 2030-12-31

Brief Summary

To learn about the safety of giving the drug brexucabtagene autoleucel to participants with relapsed/refractory B-cell ALL after treatment with inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD. Also, to learn if giving brexucabtagene autoleucel to patients with relapsed/refractory or high-risk, newly diagnosed B-cell ALL after treatment with inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD can help to control the disease.

Detailed Description

Primary Objectives:

To assess the Efficacy of Brexucabtagene autoleucel [anti-CD19 autologous derived chimeric antigen receptor T-cell (CAR-T)] in terms of EFS in patients with R/R and high-risk newly diagnosed B-cell acute lymphoblastic leukemia (B-cell ALL) post cytoreduction with mini-hyper-CVD-inotuzumab-blinatumomab/Hyper-CVAD-inotuzumab-blinatumomab

The EFS will be estimated in terms of median EFS and 9-month EFS for the R/R cohort and 18-month EFS for the frontline cohort.

Secondary Objectives:

1. 12 and 24-months overall survival (OS): 12 months for the R/R cohort and 24 months for the frontline cohort

2. Duration of persistent MRD negativity by flow cytometry and NGS at 9 and 18 months: 9 months for the R/R cohort and 18 months for the frontline cohort

3. Best Ooverall response rates [complete remission (CR) and CR with incomplete count recovery (CRi)]

4. Achievement of MRD negativity amongst patients in CR and not MRD negative before Brexucabtagene autoleucel infusion

5. Safety

Exploratory Objectives:

1. CAR-T-cell expansion ((Days 1, 4, 8, 11, 14, 21, 28, monthly up to 3 months and then every 3 months up to 24 months post infusion)

2. B-cell aplasia (Days 0, 7, 14, 28, monthly up to 3 months and then every 3 months up to 24 months post infusion)

3. Measurable residual disease (MRD) negativity by next-generation sequencing (NGS) (at 1 in 105-6 sensitivity) (PB on D14 and PB/BM: Day 28, and then Q3 months up to 24 months post infusion)

4. Cytokine panel (Days 0, 1, 2, 4, 7, 10, 14, 28)

5. Additional correlatives samples to address tumor samples and immune system factors will be collected at baseline, D28 and Q3 months. These include samples for bulk RNA sequencing of the tumor and germline and single cell RNA sequencing of CAR T-cells as also for assessing the methylation signatures of the CAR T-cells.

Conditions

Relapsed/Refractory; B-cell Acute Lymphocytic Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Phase 1B + Phase 2

Participants found to be eligible to take part in this study, you will be assigned to a study phase (Phase 1B or Phase 2). Up to 10 participants will be enrolled in Phase 1B, and up to 30 will be enrolled in Phase 2. All participants will first receive cytoreductive therapy (inotuzumab ozogamicin, blinatumomab, and either hyper-CVAD or mini-hyper-CVD), followed by lymphodepletion chemotherapy and 1 dose of brexucabtagene autoleucel.

Group Type: EXPERIMENTAL

Blinatumomab

Intervention Type: DRUG

Given by Infusion

Inotuzumab Ozogamicin

Intervention Type: DRUG

Given by IV

Hyper-CVAD

Intervention Type: DRUG

Given by IV Participants younger than 60 years of age, you will receive hyper-CVAD.

Mini-hyper-CVD

Intervention Type: DRUG

Given by IV Participants 60 years of age or older, you will receive mini-hyper-CVD

Interventions

Blinatumomab

Given by Infusion

Intervention Type: DRUG

Inotuzumab Ozogamicin

Given by IV

Intervention Type: DRUG

Hyper-CVAD

Given by IV Participants younger than 60 years of age, you will receive hyper-CVAD.

Intervention Type: DRUG

Mini-hyper-CVD

Given by IV Participants 60 years of age or older, you will receive mini-hyper-CVD

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Participants of age ≥18 years with documented relapsed or refractory B-cell ALL
• In the newly diagnosed cohort: Participants of age ≥18 years with high-risk newly diagnosed B-cell ALL defined as:

1. KMT2A rearranged ALL

2. Complex cytogenetics as per NCCN 2022

3. Low-hypodiploidy/tetraploidy

4. Philadelphia-like ALL (based on CRLF2 overexpression or recurrent Ph-like genetic fusions)

• Performance status of 0, 1, or 2
• Adequate organ function with creatinine less than or equal to 1.6 mg/dl, bilirubin less than or equal to 3.5 mg and ALT and AST less than or equal to 5 times institutional upper limit of normal
• Participants should be CD19 expression positive (>50%) before enrollment
• Participants with chronic viral infections like Hepatitis B-virus, Hepatitis C virus or Human Immunodeficiency virus I/II will be eligible if they are on therapy and infections are under control.

Exclusion Criteria

• Philadelphia positive B-cell ALL
• Pregnant or lactating; women of child-bearing potential (WOCBP) must have negative pregnancy test. WOCBP defined as not post-menopausal for 12 months or no previous surgical sterilization
• Prior exposure to brexu-cel or other anti-CD-19 CAR T cell therapy
• Active and uncontrolled disease/infection as judged by the treating physician
• Unable or unwilling to sign the consent form
• No other investigational therapy within the past 14 days

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

M.D. Anderson Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Elias Jabbour, MD

Role: PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Locations

MD Anderson Cancer Center

Houston, Texas, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Elias Jabbour, MD

Role: CONTACT

ejabbour@mdanderson.org

(713) 792-4764

Facility Contacts

Elias Jabbour, MD

Role: primary

ejabbour@mdanderson.org

713-792-4764

Related Links

http://www.mdanderson.org

MD Anderson Cancer Center

Other Identifiers

NCI-2024-01756

Identifier Type: OTHER

Identifier Source: secondary_id

2023-0627

Identifier Type: -

Identifier Source: org_study_id